Nuo Therapeutics, Inc. Reports Earnings Results for the Third Quarter Ended September 30, 2019
January 31, 2020 at 04:18 pm EST
Share
Nuo Therapeutics, Inc. announced earnings results for the third quarter ended September 30, 2019. For the third quarter, the company announced total revenue was USD 57,883 compared to USD 260,280 a year ago. Operating loss was USD 38,692 compared to USD 411,794 a year ago. Net loss was USD 92,620 compared to USD 649,878 a year ago. Basic eps was USD 0 compared to basic loss per share of USD 0.03 a year ago. For the nine months, total revenue was USD 141,277 compared to USD 558,532 a year ago. Operating loss was USD 1.042 million compared to USD 1.662 million a year ago. Net loss was USD 1.252 million compared to USD 1.910 million a year ago. Basic loss per share was USD 0.05 compared to USD 0.08 a year ago.
Nuo Therapeutics, Inc. is a regenerative therapies company. The Company is focused on developing and marketing products for chronic wound care primarily within the United States. The Company commercializes cell-based technologies that harness the regenerative capacity of the human body to trigger natural healing. Its flagship product, Aurix, is a biodynamic hematogel that uses a patientâs own platelets and plasma as a catalyst for healing. The Companyâs commercial offering consists of point of care technology for the safe and effective separation of autologous blood to produce a platelet-based therapy for the chronic wound care market. This offering is known as Aurix (the Aurix System), which produces a platelet rich plasma (PRP) gel at the point of care using the patientâs own platelets and plasma sourced from a small draw of peripheral blood. Aurix comprises a natural, endogenous complement of protein and non-protein signal molecules that contribute to effective healing.
NUO THERAPEUTICS, INC. 
